| Literature DB >> 26759720 |
Nicole Lefel1, Loes Janssen2, Jos le Noble1, Norbert Foudraine1.
Abstract
BACKGROUND: Intravenously administered iodine-containing contrast medium (CM) is associated with the development of contrast-induced nephropathy (CIN). Data on the effectiveness of sodium bicarbonate therapy in the prevention of CIN are controversial. Furthermore, the incidence of and risk factors for CIN in intensive care unit (ICU) patients are poorly defined. We investigated the effectiveness of sodium bicarbonate prophylaxis and the incidence of and risk factors for CIN in a heterogeneous ICU population.Entities:
Keywords: Contrast-induced AKI; Contrast-induced nephropathy; ICU; Prophylactic therapy
Year: 2016 PMID: 26759720 PMCID: PMC4710042 DOI: 10.1186/s40560-016-0127-6
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492
Baseline characteristics of the study population
| Variable | Total number of CT* scans ( | No prophylaxis ( | Prophylaxis ( |
|
|---|---|---|---|---|
| Male gender | 125 (59.2 %) | 99 (60.7 %) | 26 (54.2 %) | 0.42 |
| Age (years) | 65.3 (12.5) | 64.3 (12.6) | 68.6 (11.5) | 0.04 |
| Baseline sCr (μmol/L) | 77.7 (71.5) | 73.0 (53.0) | 104.5 (134.0) |
|
| Baseline GFR$ (mL/min) | 68.6 (37.9) | 73.6 (38.4) | 51.8 (31.0) |
|
| §APACHE II score | 20.4 (8.3) | 20.5 (8.5) | 20.0 (7.5) | 0.70 |
| APACHE IV score | 79.5 (30.1) | 78.6 (31.6) | 82.5 (24.4) | 0.43 |
| Predicted in-hospital mortality (%) | 35.6 % (24.2 %) | 34.4 (25.0) | 39.8 (21.2 %) | 0.18 |
| SOFA# day 1 | 5.0 (6.0) | 6.5 (5.0) | 5.0 (5.0) | 0.07 |
| SOFA day 4 | 6.0 (5.0) | 6.0 (7.0) | 4.0 (5.0) | 0.02 |
| Comorbidities | ||||
| Diabetes | 32 (15.2 %) | 31 (19.0 %) | 1 (2.1 %) |
|
| Heart failure | 11 (5.2 %) | 6 (3.7 %) | 5 (10.4 %) | 0.09 |
| Sepsis | 56 (26.5 %) | 42 (25.8 %) | 14 (29.2 %) | 0.64 |
| Haemoglobin < 6 (mmol/L) | 57 (27.0 %) | 42 (25.8 %) | 15 (31.3 %) | 0.45 |
| Fluid balance | 2529 (4701) | 2401 (4639) | 3123 (5695) | 0.54 |
| Patients receiving norepinephrine | 54 (25.6 %) | 43 (26.4 %) | 11 (22.9 %) | 0.63 |
| Patients receiving aminoglycosides | 12 (5.7 %) | 10 (6.1 %) | 2 (4.2 %) | 1.00 |
Dichotomous data are noted as the number of CT scans with the presence of the concerning variable in that group (percentage of the total number of CTs). Continuous data are noted as the mean (standard deviation) or median (interquartile range)
* CT computed tomography, $ GFR glomerular filtration rate, sCr serum creatinine level, § APACHE Acute Physiology and Chronic Health Evaluation,# SOFA Sequential Organ Failure Assessment
Effectiveness of sodium bicarbonate prophylaxis for the prevention of contrast-induced nephropathy in cases with or without pre-existing renal impairment
| GFR > 60 mL/min ( | GFR < 60 mL/min ( | |||||
|---|---|---|---|---|---|---|
| No prophylaxis ( | Prophylaxis ( |
| No prophylaxis ( | Prophylaxis ( |
| |
| No CIN | 88 (88.0 %) | 13 (86.7 %) | 1.00 | 36 (57.1 %) | 16 (48.5 %) | 0.42 |
| CIN | 12 (12.0 %) | 2 (13.3 %) | 27 (42.9 %) | 17 (51.5 %) | ||
| RRT/CIN | 3/12 (25.0 %) | 0/2 (0.0 %) | 1.00 | 7/27 (25.9 %) | 2/17 (11.8 %) | 0.27 |
Dichotomous data are noted as the number of CT scans with the presence of the concerning variable in that group (percentage of the total number of CT scans)
CIN contrast-induced nephropathy, RRT renal replacement therapy, GFR glomerular filtration rate
Characteristics of patients who did or did not develop contrast-induced nephropathy
| No CIN | CIN |
| |
|---|---|---|---|
| Number of CT scans | 153 (72.5 %) | 58 (27.5 %) | |
| Age (years) | 64 (13) | 69 (10) | <0.01 |
| Male gender | 88 (57.5 %) | 37 (63.8 %) | 0.41 |
| Diabetes mellitus | 22 (14.4 %) | 10 (17.2 %) | 0.61 |
| Heart failure | 6 (3.9 %) | 5 (8.6 %) | 0.18 |
| Sepsis | 41 (26.8 %) | 15 (25.9 %) | 0.89 |
| Baseline GFR < 60 mL/min | 52 (34.0 %) | 44 (75.9 %) | <0.01 |
| Haemoglobin (mmol/L) | 6.6 (1.1) | 6.2 (0.88) | 0.01 |
| APACHE II score | 19.5 (7.9) | 22.8 (8.9) | <0.01 |
| APACHE IV score | 74.5 (29.1) | 92.6 (28.9) | <0.01 |
| SOFA day 1 | 8.0 (7.0) | 5.0 (4.0) | <0.01 |
| SOFA day 4 | 11.0 (6.0) | 4.0 (3.0) | <0.01 |
| Fluid balance (mL/24 h) | 2180 (4566) | 3488 (7251) | 0.03 |
| Aminoglycoside (single-dose) use | 5 (3.3 %) | 7 (12.1 %) | 0.02 |
| Norepinephrine use | 32 (20.9 %) | 22 (37.9 %) | 0.01 |
| Prophylactic therapy | 29 (19.0 %) | 19 (32.8 %) | 0.03 |
Dichotomous data are noted as the number of patients with the presence of the concerning variable in that group (percentage of the entire population). Continuous data are noted as the mean (standard deviation) or median (interquartile range)
CIN contrast-induced nephropathy, CT computed tomography, GFR glomerular filtration rate, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment
Causes of mortality
| Cause | Prophylaxis | Total | |
|---|---|---|---|
| Yes | No | ||
| MODS | 12 | 6 | 18 |
| Sepsis | 8 | 4 | 12 |
| Respiratory insufficiency | 3 | 0 | 3 |
| Anoxic encephalopathy | 2 | 0 | 2 |
| Bleeding | 2 | 0 | 2 |
| Combined respiratory and cardiac failure | 0 | 2 | 2 |
| Total | 27 | 12 | 39 |
MODS multiple organ dysfunction syndrome
No significant differences were found between patients with or without prophylaxis
Risk factors for contrast-induced nephropathy in intensive care unit patients (multivariate logistic regression analysis)
| Variable | OR |
|
|---|---|---|
| Prophylactic pre- and post-hydration (Y/N) | 1.32 | 0.49 |
| GFR < 60 mL/min or >60 mL/min | 4.41 | <0.01 |
| APACHE IV score (per increasing point) | 1.02 | 0.02 |
| Norepinephrine use (Y/N) | 1.49 | 0.32 |
| Aminoglycoside use (Y/N) | 3.87 | 0.05 |
| Fluid balance (per ml) | 1.00 | 0.95 |
| Haemoglobin (>mmol/L) | 0.64 | 0.03 |
| Age (/year) | 1.02 | 0.37 |
All variables that differed significantly between the no CIN and the CIN groups in a univariate test (Table 4) were included in the multivariate regression analysis, except for the APACHE II score. This score is highly correlated with APACHE IV and therefore was discarded from the multivariate analysis
GFR glomerular filtration rate, OR odds ratio, APACHE Acute Physiology and Chronic Health Evaluation